Temozolomide in Glioblastoma Therapy: Role of Apoptosis, Senescence and Autophagy. Comment on Strobel et al., Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. Biomedicines 2019, 7, 69

Temozolomide, a DNA methylating drug, is currently being used first-line in glioblastoma therapy. Although the mode of action of this so-called S(N)1 alkylating agent is well described, including the types of induced DNA damage triggering the DNA damage response and survival and death pathways, some...

Descripción completa

Detalles Bibliográficos
Autor principal: Kaina, Bernd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966492/
https://www.ncbi.nlm.nih.gov/pubmed/31717973
http://dx.doi.org/10.3390/biomedicines7040090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966492/
https://www.ncbi.nlm.nih.gov/pubmed/31717973
http://dx.doi.org/10.3390/biomedicines7040090

Ejemplares similares